<unk>  (REGN727 and SAR236553) is an investigational human monoclonal antibody that inhibits PCSK9 for the treatment of hypercholesterolemia.<unk>  is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerostic cardiovascular disease, who require additional lowering of LDL-C. The effect of<unk>  on cardiovascular morbidity and mortality has not been determined.
Alirocumab
Evolocumab
Ustekinumab
Nebacumab
Durvalumab
Burosumab
Lanadelumab
Avelumab